Two listings can use different names for the same intended substance, or similar names for different substances. Neither possibility can be resolved from the price alone. For no-DAC CJC, the naming problem is particularly important because the familiar CJC name also appears in long-acting research.
An analytical identification paper described a 29-amino-acid preparation marketed under the CJC name. The original long-acting development paper describes an albumin-binding construct. This history is a reason to check structure, not assume that every CJC reference identifies the same material.
What should match?
A meaningful identity comparison includes the amino-acid sequence, terminal modifications and whether an albumin-binding feature is present. The stated salt and analytical reference may also matter. An alias can help locate records, but it cannot replace those attributes.
“Modified GRF” is therefore best treated as a claimed identity that needs a defined modification record. The word “modified” does not tell a reader which changes were made. Similarly, “no DAC” says what is purportedly absent without completely specifying what is present.
Price differences can arise for many reasons unrelated to molecular identity. They do not establish purity, activity, sterility or clinical value. A more expensive listing is not automatically a different or better studied peptide.
This distinction also changes how research should be cited. A study of an albumin-binding construct cannot validate a no-DAC label simply because both use CJC in the title. Matching must happen at the intervention level before its findings are applied.
For a reader comparing information, the productive question is not which name sounds more scientific. It is whether the stated chemical identity can be connected to the exact study and the exact batch. If that connection is missing, the uncertainty should remain visible rather than being resolved by a synonym list or a seller's price.